Enobosarm - PharmaKB

Enobosarm

Enobosarm is a small molecule pharmaceutical. It is currently being investigated in clinical studies.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

16 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	—	5	2	—	—	7
Wasting syndrome	D019282	—	—	—	1	2	—	—	3
Cachexia	D002100	HP_0004326	R64	—	1	2	—	—	3
Muscular atrophy	D009133	HP_0003202	—	—	1	2	—	—	3
Non-small-cell lung carcinoma	D002289	—	—	—	—	2	—	—	2
Lung neoplasms	D008175	HP_0100526	C34.90	—	—	2	—	—	2

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Urinary incontinence	D014549	HP_0000020	R32	—	4	—	—	—	4
Stress urinary incontinence	D014550	HP_0010992	—	—	4	—	—	—	4
Enuresis	D004775	—	R32	—	4	—	—	—	4
Triple negative breast neoplasms	D064726	—	—	—	2	—	—	—	2
Obesity	D009765	EFO_0001073	E66.9	—	1	—	—	—	1

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast density	D000071060	—	—	1	—	—	—	—	1

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Enobosarm
INN	enobosarm
Description	Enobosarm, also formerly known as ostarine and by the developmental code names GTx-024, MK-2866, and S-22, is a selective androgen receptor modulator (SARM) which is under development for the treatment of androgen receptor-positive breast cancer in women and for improvement of body composition (e.g., prevention of muscle loss) in people taking GLP-1 receptor agonists like semaglutide. It was also under development for a variety of other indications, including treatment of cachexia, Duchenne muscular dystrophy, muscle atrophy or sarcopenia, and stress urinary incontinence, but development for all other uses has been discontinued. Enobosarm was evaluated for the treatment of muscle wasting related to cancer in late-stage clinical trials, and the drug improved lean body mass in these trials, but it was not effective in improving muscle strength. As a result, enobosarm was not approved and development for this use was terminated. Enobosarm is taken by mouth.
Classification	Small molecule
Drug class	selective androgen receptor modulator (non-steroidal)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1